Congenital myofibromatosis in two siblings.

Fabio Arcangeli
Fabio Arcangeli
Centro Studi GISED
Donato Calista
Donato Calista
National Cancer Institute
United States

Eur J Dermatol 2006 Mar-Apr;16(2):181-3

Department of Dermatology, M. Bufalini Hospital, Viale Ghirotti, 286, 47023 Cesena, Italy.

Infantile myofibromatosis (IM) is a rare mesenchymal disorder characterized by solitary or multiple nodules involving the skin, striated muscles, bones and, sometimes, viscera. Although most cases are sporadic, there have been a few reports of a familial pattern of inheritance. In most cases, diagnosing IM is not difficult. However, IM should be differentiated from neurofibromatosis, paediatric sarcomas, nodular fasciitis, fibrous hamartoma of infancy, and hyaline juvenile fibromatosis. The prognosis for IM depends on the degree of visceral involvement. Since spontaneous tumoral regression is usual, in cases of limited involvement therapeutic abstention and patient observation are recommended. Surgery, chemotherapy or radiotherapy are reserved for patients with multiple visceral localizations, particularly in the lung and gastrointestinal tract, which may have a worse prognosis and potentially fatal outcome. We report on a family in which two siblings, born from non-consanguineous parents, were affected by congenital myofibromatosis. In both patients, tumors were present at birth, with multicentric subcutaneous, muscular, skeletal and visceral involvement. The growing subcutaneous myofibromas were surgically removed, while the smallest ones disappeared spontaneously over the course of 24 months.
November 2006
8 Reads

Similar Publications

[Familial infantile myofibromatosis].

Ann Dermatol Venereol 2009 Apr 26;136(4):346-9. Epub 2009 Feb 26.

Service de dermatologie, CHU Saint-Jacques, 2, place Saint-Jacques, 25000 Besançon cedex, France.

Background: Infantile myofibromatosis (IM) is the most common fibrous disorder of infancy and childhood. It is characterized by congenital tumours of the skin, striated muscle, bones and viscera. Most cases are sporadic and few familial cases have been reported. Read More

View Article
April 2009

Multicentric infantile myofibromatosis.

Int J Pediatr Otorhinolaryngol 1998 Oct;45(3):249-54

Department of Otolaryngology-Head and Neck Surgery, Emory University, Atlanta, GA 30322, USA.

Infantile myofibromatosis (IM) is a rare tumor of infancy and childhood, typically presenting as a firm, nodular mass involving soft tissue, bone or viscera. Approximately one-third of cases involve the head and neck. These tumors can be solitary or multicentric. Read More

View Article
October 1998

Infantile myofibromatosis.

Med J Malaysia 2001 Dec;56(4):497-9

Department of Paediatrics, University of Malaya Medical Centre, Kuala Lumpur.

Infantile myofibromatosis (IMF) is a rare tumour with a wide spectrum of disease activity ranging from a solitary cutaneous nodule through to a multicentric form with widespread visceral involvement. It is characterised by its unique ability to spontaneously regress and has a typical histological appearance of actin-positive fibroblasts arranged in whorls or fascicles and vessels in a pericytomatous pattern. A male infant with multiple lesions involving the subcutaneous tissue and bone from birth is described and followed-up for two years. Read More

View Article
December 2001

A case of congenital multiple myofibromatosis developing in an infant.

Pediatrics 1999 Jul;104(1 Pt 1):113-5

Department of Medicine, Division of Dermatology, University of Louisville, KY 40202, USA.

Background: Infantile myofibromatosis is marked by the development of firm, discrete, flesh-colored to purple nodules in skin, muscle, bone, and/or subcutaneous tissues. In cases without visceral involvement, the prognosis is excellent with expected spontaneous regression of nodules in 1 to 2 years. Visceral lesions are associated with significant morbidity and mortality generally within the first few months of life secondary to obstruction of a vital organ, failure to thrive, or infection. Read More

View Article
July 1999